- Home
- STHO vs GNLX Comparison
STHO vs GNLX Comparison
Compare STHO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STHO | GNLX |
|---|---|---|
| Founded | 2022 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 124.8M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | STHO | GNLX |
|---|---|---|
| Price | $8.75 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 46.9K | ★ 186.6K |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.73 | 18.10 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,143,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.06 | $1.99 |
| 52 Week High | $9.40 | $8.54 |
Technical Indicators
Market Signals| Indicator | STHO | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 53.48 |
| Support Level | $7.72 | $2.31 |
| Resistance Level | $9.23 | $3.11 |
| Average True Range (ATR) | 0.27 | 0.16 |
| MACD | 0.08 | 0.09 |
| Stochastic Oscillator | 81.65 | 94.96 |
Price Performance
Historical ComparisonAbout STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.